Cover Story

New indications may accelerate ‘explosion’ in CAR T-cell therapy, but more education still needed

HemOnc Today, March 25, 2019
Years of research into chimeric antigen receptor T-cell therapy for cancer treatment is finally paying dividends. When Renier J. Brentjens, MD
Feature

Patient feedback can help ensure balance between cancer treatment efficacy, tolerability

March 18, 2019
Researchers have launched a research consortium that they hope will identify efficient methods to incorporate patient-reported outcomes into clinical…
Feature

Biomarker may help better predict outcomes in HPV-positive head, neck cancer

March 15, 2019
Researchers have identified a gene panel that could lead to less intensive treatment for certain patients with HPV-positive oropharyngeal squamous…
Feature

Sex differences in glioblastoma could lead to tailored treatments, improved outcomes

March 14, 2019
Researchers at Washington University School of Medicine in St. Louis have identified distinct molecular signatures of glioblastoma that may explain…
Feature

Group to study immunotherapy-targeted therapy combination for metastatic colon cancer

March 7, 2019
Researchers at University of Colorado Cancer Center and partnering institutions received a grant to study a novel combination therapy for patients…
Pharmacology Consult

Risk-based approach must guide VTE prophylaxis for ambulatory patients with cancer

HemOnc Today, February 25, 2019
Jai N. Patel, PharmD, BCOP
Individuals with cancer are more than four times as likely as those in the general population to develop venous thromboembolism. Chemotherapy receipt…
Editorial

Prostate cancer trials: Waiting for Godot

HemOnc Today, February 25, 2019
Derek Raghavan, MD, PhD
In an era in which we are ever more hurrying to find truth, and the FDA is exploring a range of surrogate endpoints to support early introduction of…
Point/Counter

Will targeted therapies become the mainstay of AML treatment?

HemOnc Today, February 25, 2019
POINT After a long drought, the past 2 years have seen a flurry of drug approvals in AML, including three highly specific agents that target discrete…
Cover Story

Targeted treatments for acute myeloid leukemia yield modest improvements, great hope

HemOnc Today, February 25, 2019
Acute myeloid leukemia historically has been one of the more deadly and difficult-to-treat cancers, with a 5-year survival rate below 30%. Moreover…
Feature

Rose geranium oil may improve nasal symptoms associated with cancer-directed therapy

February 12, 2019
Rose geranium oil appeared to ease the symptoms of nasal vestibulitis — a common condition associated with cancer treatment — among a…